Northcoast Research Comments on Cardiovascular Systems Inc’s Q3 2018 Earnings (CSII)
Cardiovascular Systems Inc (NASDAQ:CSII) – Equities research analysts at Northcoast Research issued their Q3 2018 EPS estimates for shares of Cardiovascular Systems in a research note issued to investors on Thursday. Northcoast Research analyst D. Keiser expects that the medical device company will post earnings of ($0.01) per share for the quarter. Northcoast Research also issued estimates for Cardiovascular Systems’ Q4 2018 earnings at $0.04 EPS, FY2018 earnings at ($0.04) EPS, Q1 2019 earnings at $0.03 EPS, Q2 2019 earnings at $0.06 EPS, Q3 2019 earnings at $0.07 EPS, Q4 2019 earnings at $0.12 EPS and FY2019 earnings at $0.28 EPS.
Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Cardiovascular Systems had a negative net margin of 1.62% and a negative return on equity of 0.51%. The business had revenue of $52.63 million for the quarter, compared to analyst estimates of $53.39 million. During the same period last year, the firm earned $0.03 earnings per share. Cardiovascular Systems’s revenue for the quarter was up 5.2% compared to the same quarter last year.
Cardiovascular Systems (NASDAQ:CSII) traded up $0.44 during trading hours on Monday, reaching $22.84. 614,400 shares of the company were exchanged, compared to its average volume of 284,714. Cardiovascular Systems has a 1-year low of $21.03 and a 1-year high of $33.11. The company has a market capitalization of $744.09, a price-to-earnings ratio of -228.38 and a beta of 2.32. The company has a current ratio of 4.30, a quick ratio of 3.83 and a debt-to-equity ratio of 0.18.
Hedge funds have recently added to or reduced their stakes in the business. BlueCrest Capital Management Ltd bought a new position in Cardiovascular Systems in the 2nd quarter valued at about $204,000. Advisor Group Inc. increased its holdings in Cardiovascular Systems by 0.4% in the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock valued at $263,000 after buying an additional 35 shares during the period. JPMorgan Chase & Co. increased its holdings in Cardiovascular Systems by 34.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock valued at $265,000 after buying an additional 2,115 shares during the period. UBS Asset Management Americas Inc. increased its holdings in Cardiovascular Systems by 9.5% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 9,193 shares of the medical device company’s stock valued at $296,000 after buying an additional 800 shares during the period. Finally, Trexquant Investment LP bought a new position in Cardiovascular Systems in the 3rd quarter valued at about $276,000. 74.22% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2018/02/13/northcoast-research-comments-on-cardiovascular-systems-incs-q3-2018-earnings-csii.html.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.